Fredrik Palm, CEO of ContextVision, has on October 22nd, 2021 purchased 2,500 shares in ContextVision AB at an average price of NOK 22.47 per share. After the transaction, Mr Palm holds a total of 30,700 shares in ContextVision AB.
Martin Ingvar, Member of the Board of ContextVision, has on October 21, 2021 purchased 6,000 shares in ContextVision AB at an average price of NOK 22.10 per share. After the transaction, Mr Ingvar holds a total of 12,000 shares in ContextVision AB.
ContextVision has decided to build its first fully digital pathology laboratory – thus confirming its strong dedication to advancing digitalization within pathology, for the best of both patients and the medical profession.
INIFY Prostate® shown to accurately outline suspicious prostate cancer in study with two prominent medical centers
ContextVision today announced that results from a US clinical evaluation were presented at the Pathology Visions Congress in Las Vegas, USA.